By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


SEARCH JOBS

Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.


Key Statistics


Email:
Ownership: Public

Web Site: Alexion
Employees: 1,500
Symbol: ALXN
 



Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Alexion (ALXN) Release: Late-Breaking Data Presented At European Hematology Association: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase I/II Study Exhibit Rapid And Sustained Reductions In LDH 6/10/2016 8:18:46 AM
Alexion (ALXN) Announces Topline Results From Phase III REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) 6/6/2016 2:31:30 PM
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 6/2/2016 12:02:14 PM
Alexion (ALXN) To Present At Upcoming Investor Conferences 5/31/2016 11:11:11 AM
Alexion (ALXN) Release: Researchers To Present Late-Breaking Data On ALXN1210 In Patients With PNH At European Hematology Association Annual Congress 5/19/2016 12:13:56 PM
Alexion (ALXN) To Present At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 11:07:42 AM
Alexion (ALXN) Reports First Quarter 2016 Results 4/28/2016 10:54:43 AM
X-Chem Announces Achievement Of Milestone In Alexion (ALXN) Collaboration 4/27/2016 8:44:59 AM
Alexion (ALXN) Release: Data Presented At ENDO 2016 Show Sustained Improvements In Survival Rates, Bone Healing, Respiratory Support And Physical Function In Children With Hypophosphatasia (HPP) Receiving Long-Term Treatment With Strensiq (Asfotase Alfa) 4/4/2016 10:40:50 AM
Alexion (ALXN) Release: Kanuma (Sebelipase Alfa) Receives Marketing Approval In Japan For Treatment Of Patients With Lysosomal Acid Lipase Deficiency (LAL-D) 3/28/2016 9:16:34 AM
12345678910...
//-->